Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Health economic evaluations of genomic newborn screening: Approaches by studies within the international consortium on newborn sequencing.

European journal of human genetics : EJHG·2026

Same author

A Validated Prognostic Score for Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy.

Neurology·2026

Same author

Clinical Characterization of Patients With 5q Spinal Muscular Atrophy Types 2 and 3 in Brazil: A Cross-Sectional Observational Study.

Clinical genetics·2026

Same author

Unmet Needs in the Care of Patients with Duchenne Muscular Dystrophy in Brazil.

Arquivos de neuro-psiquiatria·2026

Same author

Analytical Validation of a Genomic Newborn Screening Workflow.

International journal of neonatal screening·2025

Same author

Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee.

Neurology·2025

Search research articles

Related Experiment Video

Updated: May 6, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Why should a 5q spinal muscular atrophy neonatal screening program be started?

Michele Michelin Becker¹, Flávia Nardes², Tamara Dangouloff³

¹Hospital de Clínicas de Porto Alegre, Unidade de Neurologia Pediátrica, Departamento de Pediatria, Porto Alegre RS, Brazil.

Arquivos De Neuro-Psiquiatria

|October 13, 2024

Summary

Newborn screening for spinal muscular atrophy (SMA) is crucial for early treatment and improved outcomes. Implementing this screening program is urgent and cost-effective for managing this genetic neuromuscular disorder.

More Related Videos

Intravenous Injections in Neonatal Mice

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

Related Experiment Videos

Last Updated: May 6, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Intravenous Injections in Neonatal Mice

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

Area of Science:

Neurology
Genetics
Pediatrics

Background:

Spinal muscular atrophy (SMA) is a progressive genetic neuromuscular disorder.
Early diagnosis and treatment significantly improve patient prognosis.
Newborn screening for SMA is becoming increasingly available globally.

Purpose of the Study:

To review the current status and importance of newborn screening for SMA.
To advocate for the urgent implementation of SMA neonatal screening programs.
To address concerns regarding the cost-effectiveness of SMA screening.

Main Methods:

Literature review of existing studies and guidelines on SMA and newborn screening.
Analysis of the impact of early treatment on SMA outcomes.
Evaluation of the economic aspects of implementing SMA neonatal screening.

Main Results:

Timely initiation of disease-modifying therapies in SMA leads to better clinical outcomes.
Newborn screening enables earlier detection and treatment initiation.
Well-organized screening programs are essential for maximizing benefits and managing healthcare costs.

Conclusions:

Neonatal screening for SMA is a critical public health initiative.
Early detection through screening is paramount for improving the lives of children with SMA.
Implementing SMA newborn screening is cost-effective and does not necessitate increased healthcare expenditure.